Form 8-K

8-K — InspireMD, Inc.

Accession: 0001493152-26-038624

Filed: 2026-08-17

Period: 2026-08-17

CIK: 0001433607

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001433607

2026-08-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 17, 2026

InspireMD,

Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-35731

26-2123838

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

6303

Waterford District Drive, Suite 215

Miami,

Florida 33126

33126

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (888) 776-6804

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.0001 par value per share

NSPR

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition

August 17, 2026, InspireMD, Inc. (the “Company”) issued a press release announcing its financial and operating results and

recent highlights for the three and six months ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1 and

is incorporated herein by reference.

accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to

this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as

amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference

into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as

shall be expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Number

Description

99.1

Press release, dated August 17, 2026 (furnished herewith pursuant to Item 2.02)

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

INSPIREMD,

INC.

Date:

August 17, 2026

By:

/s/

Marvin Slosman

Name:

Marvin Slosman

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

InspireMD

Reports Second Quarter 2026 Financial Results

Company to host investor conference call today, August 17th, at 8:30am EDT -

Miami,

FL — August 17, 2026 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer

of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results

for the three and six months ended June 30, 2026.

Recent

Business Highlights:

● Generated

revenue of $1.8 million in the second quarter of 2026, in line with the second quarter of

2025. Robust growth of 21% in international markets was driven by broad-based increases in

demand across most countries, offset by the impact of the voluntary recall in the U.S. of

the CGuard Prime 135 cm delivery system in May.

● Announced

the appointment of carotid intervention commercial leader Kathleen Kennedy as Senior Vice

President of Global Sales and Marketing to support the anticipated U.S. re-launch of the

CGuard platform.

● Identified

and implemented design changes to the CGuard Prime 135 cm delivery system to address the

technical challenges identified following U.S. launch; design modifications now undergoing

validation and performance testing ahead of FDA submission.

● Commenced

patient enrollment activity in the Company’s CGUARDIANS III pivotal trial of its SwitchGuard

neuroprotection system (“NPS”), for use with its CGuard Prime 80 cm stent platform,

in TCAR procedures.

● Announced

30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80 cm implant for

use in TCAR procedures. Key highlights include:

○ Acute

device success was achieved in 100% (50/50) of patients;

○ No

deaths, strokes, or myocardial infarctions were reported within 30 days;

○ No

stent thrombosis was observed within 30 days;

○ Complete

stent patency observed at 30 days in evaluable subjects.

● Following

the end of the second quarter of 2026, initiated savings actions designed to reduce the cost

structure, improve operational efficiency, and better align the Company’s resources

with its strategic priorities, expected to generate annual savings of approximately $9 million.

“Following

the end of the second quarter, we executed a series of steps designed to consolidate resources and better align our global operations

with our near-term commercial and regulatory priorities, including streamlining our commercial organization to more effectively support

our anticipated U.S. platform re-launch,” stated Marvin Slosman, Chief Executive Officer. “We continue to engage in a productive

dialogue with FDA regarding our pending regulatory submissions for our CGuard Prime 80 cm implant for TCAR procedures, as well as our

original CGuard platform for traditional carotid stenting procedures. We continue to anticipate FDA decisions on both products later

this year.”

“At

the same time, the design improvements that we are making to the CGuard Prime 135 cm delivery system, which we voluntarily recalled last

quarter, are progressing as planned, with an FDA submission anticipated before year-end,” continued Mr. Slosman. “Subject

to receipt of the necessary regulatory approvals, we expect to return to the U.S. market with both TCAR and CAS delivery systems. We

believe that this would strengthen our ability to compete in the carotid stenting market, and support increased adoption of the CGuard

platform, expanded market penetration and future revenue growth, leveraging what we believe is a best-in-class implant in the carotid

stenting space.”

Financial

Results for the Second Quarter Ended June 30, 2026

For

the second quarter of 2026, total revenue was $1,771,000, a decrease of $7,000, or 0.4%, compared to $1,778,000 for the second quarter

of 2025.

U.S.

revenue for the second quarter of 2026 was $(351,000), compared to $27,000 for the second quarter of 2025. Net U.S. revenue was negative

for the quarter, reflecting $734,000 of customer credits issued in connection with the voluntary recall of the CGuard Prime 135 cm delivery

system, which exceeded gross U.S. product sales prior to the initiation of the recall. International revenue was $2,122,000, an increase

of 21%, compared to $1,751,000 for the second quarter of 2025.

Gross

loss (revenue less cost of revenues) for the second quarter of 2026 was $774,000, compared to gross profit of $313,000, or 17.6% of revenue,

for the second quarter of 2025. Gross loss for the second quarter of 2026 included an inventory impairment of $612,000 and the aforementioned

revenue credits of $734,000, both associated with the voluntary recall action. On a non-GAAP basis, which excludes the inventory impairment

charge and revenue credits as calculated in the attached non-GAAP reconciliation table, adjusted gross profit for the second quarter

of 2026 was $572,000.

Total

operating expenses for the second quarter of 2026 were $13,671,000, an increase of $339,000, or 2.5%, compared to $13,332,000 for the

second quarter of 2025. The increase was primarily due to greater headcount-related expenses for the U.S. commercial team, higher development,

clinical and regulatory expenses related to SwitchGuard NPS and CGuard Prime 80 cm, partially offset by lower general and administrative

compensation expenses.

Financial

income, net, for the second quarter of 2026 was $121,000, compared to financial expense, net, of $132,000 for the second quarter of 2025.

Net

loss for the second quarter of 2026 totaled $14,324,000, or $0.17 per basic and diluted share, compared to a net loss of $13,151,000,

or $0.26 per basic and diluted share, for the same period in 2025.

of June 30, 2026, cash and cash equivalents and marketable securities were $30,421,000, compared to $54,211,000 as of December 31, 2025.

Financial

Results for the Six Months Ended June 30, 2026

For

the first six months of 2026, total revenue increased by $1,862,000, or 56.3%, to $5,169,000, from $3,307,000 for the same period of

2025. U.S. revenue was $827,000, while international revenue was $4,342,000, representing a 33% year-over- year increase compared to

the first six months of 2025.

Gross

loss (revenue less cost of revenues) for the six months ended June 30, 2026, was $87,000, compared to gross profit of $605,000, or 18.3%

of revenue, for the same period of 2025. Gross loss for the six months ended June 30, 2026, included inventory-related charges totaling

$1,085,000, consisting of a $612,000 inventory impairment charge associated with the voluntary recall action and a $473,000 charge associated

with obsolete inventory, combined with the previously mentioned revenue credits of $734,000. On a non-GAAP basis, which excludes the

inventory impairment charge and revenue credits as calculated in the attached non-GAAP reconciliation table, adjusted gross profit for

the six months ended June 30, 2026, was $1,732,000.

Total

operating expenses for the six months ended June 30, 2026 were $28,336,000, an increase of $3,252,000, or 13.0%, compared to $25,084,000

for the six months ended June 30, 2025. The increase was primarily due to greater headcount-related expenses for the U.S. commercial

team, higher clinical trial expenses, and increased compensation expenses due to the hiring of new employees in connection with our expansion

in the United States, partially offset by lower general and administrative compensation expenses.

Financial

income, net, for the six months ended June 30, 2026 was $410,000, compared to $162,000 for the same period of 2025.

Net

loss for the six months ended June 30, 2026 totaled $28,013,000, or $0.33 per basic and diluted share, compared to a net loss of $24,317,000,

or $0.48 per basic and diluted share, for the same period in 2025.

Conference

Call and Webcast Details

Management

will host a conference call at 8:30 am EDT today, August 17th, to review financial results and provide an update on corporate

developments. Following management’s formal remarks, there will be a question-and-answer session.

Parties

interested in participating by phone should register using this online form. After registering for the webcast, dial-in details

will be provided in an auto-generated email containing a link to the conference number along with a personal pin.

live audio webcast and an archive of the recording will be available here and through the Investors page of InspireMD’s

corporate website at https://investors.inspiremd.com.

About

InspireMD, Inc.

InspireMD

seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by

providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under

the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information,

please visit www.inspiremd.com.

Forward-looking

Statements

This

press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements

regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future

financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words

“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”

“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”

“potential”, “scheduled” or similar words. In particular, forward-looking statements in this press release include

the Company’s expectations regarding potential FDA approvals for original CGuard and the CGuard Prime 80 cm stent for TCAR procedures,

the Company’s expectations regarding enhancements to the CGuard Prime 135 cm delivery system, the Company’s expectations

regarding its ability to return to the U.S. market with both TCAR and CAS delivery systems; the Company’s ability to compete effectively

in the carotid stenting market and increase adoption of its products; expectations regarding market penetration, commercialization, revenue

growth and future operating performance; the anticipated benefits of recent organizational and cost-saving initiatives, including expected

annualized savings and improved operational efficiency; and the Company’s strategic priorities, growth plans and future business

prospects. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various

known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified

and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks

and uncertainties include, without limitation, risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime

135 cm delivery system, including current and future costs associated with the recall, including refunds or inventory write-off costs

and other remediation costs, loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements

to CGuard Prime 135 cm delivery system, potential actions by regulators or other governmental entities associated with the recall, potential

claims and lawsuits by customers and patients, including class action product liability lawsuits, other operational impacts and consequences

of the recall, such as business disruption and distraction of management and other key employees; the Company’s history of recurring

losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of

its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern;

the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be

costly or difficult to obtain and could dilute out stockholders’ ownership interests; the clinical development, commercialization

and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive

of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative

clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing

standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses,

future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected

costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and

its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data

collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an

attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having

substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales,

distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of

the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier;

technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price

increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and

whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully

obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local

government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business

in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges,

burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and

economic instability in the Middle East that could harm the Company’s business, including due to the current security situation

in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions

and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements

and the impact of such policies on the Company, its customers and suppliers, and the global economic environment. More detailed information

about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s

filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly

Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at

http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new

information, future events or otherwise.

Non-GAAP

Financial Measures

supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting

Principles (“GAAP”), this press release and the accompanying tables include supplemental financial information, referred

to as non-GAAP financial measure, that have not been prepared in accordance GAAP, including adjusted gross profit. The Company believes

that the use of non-GAAP accounting measures is useful to its investors as an additional tool to enhance the overall understanding of

past financial performance and future prospects, and allow for greater transparency with respect to key measures used by management in

its financial and operational decision making. The Company defines adjusted gross profit as gross profit excluding the impact of the

inventory impairment charges and customer credits recognized during the periods.

The

non-GAAP financial data are not measures of the Company’s financial performance under GAAP and should not be considered as alternatives

to gross margin or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information

that is directly comparable to that provided by other companies in other industries or within InspireMD’s industry, as other companies

may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations

in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different

from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s

reported financial results. Further, the reserve for inventory impairment recognized during the period is a significant item that affects

gross profit and may obscure the Company’s underlying operating performance and comparability between periods.

The

presentation of non-GAAP financial information is not meant to be considered in isolation, as a substitute for, or superior to the directly

comparable financial measures prepared in accordance with GAAP. In addition, non-GAAP measures should not be construed as an inference

that the Company’s future results will be unaffected by unusual or non-recurring items. InspireMD urges investors to review the

financial results calculated in accordance with GAAP and the reconciliation of the Company’s non-GAAP financial measures to the

comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.

Investor

Contacts:

Jeff

Warren

LifeSci

Advisors

jwarren@lifesciadvisors.com

investor-relations@inspiremd.com

CONDENSED

CONSOLIDATED STATEMENTS OF OPERATIONS(1)

(Unaudited)

(U.S.

dollars in thousands, except share and per share data)

Three

months ended

June

30,

Six

months ended

June

30,

2026

2025

2026

2025

Revenues

$ 1,771

$ 1,778

$ 5,169

$ 3,307

Cost

of revenues

2,545

1,465

5,256

2,702

Gross

Profit

(774 )

313

(87 )

605

Operating

Expenses:

Research

and development

4,295

3,834

9,058

7,893

Selling

and marketing

5,221

4,172

10,401

6,922

General

and administrative

4,155

5,326

8,877

10,269

Total

operating expenses

13,671

13,332

28,336

25,084

Loss

from operations

(14,445 )

(13,019 )

(28,423 )

(24,479 )

Financial

income (expense), net

121

(132 )

410

162

Net

Loss

$ (14,324 )

$ (13,151 )

$ (28,013 )

$ (24,317 )

Net

loss per share – basic and diluted

$ (0.17 )

$ (0.26 )

$ (0.33 )

$ (0.48 )

Weighted

average number of common stock used in computing net loss per share – basic and diluted

84,659,943

51,003,900

84,236,742

50,508,660

CONDENSED

CONSOLIDATED BALANCE SHEETS (2)

(Unaudited)

(U.S.

dollars in thousands, except share and per share data)

June 30,

2026

December 31,

2025

ASSETS

Current Assets:

Cash and cash equivalents

$ 15,149

$ 8,939

Marketable securities

15,272

45,272

Accounts receivable:

Trade, net

1,816

2,168

Other

592

400

Prepaid expenses

1,098

1,296

Inventory

2,701

3,396

Total current assets

36,628

61,471

Non-current assets:

Long term deposit

450

442

Property, plant and equipment, net

3,858

3,584

Operating lease right of use assets

2,428

2,758

Funds in respect of employee rights upon retirement

1,277

1,149

Total non-current assets

8,013

7,933

Total assets

$ 44,641

$ 69,404

June

30,

2026

December

31,

2025

LIABILITIES

AND EQUITY

Current

liabilities:

Accounts

payable and accruals:

Trade

$ 1,654

$ 1,255

Other

7,992

9,457

Total

current liabilities

9,646

10,712

Long-term

liabilities:

Operating

lease liabilities net of current maturities

1,969

2,224

Liability

for employee rights upon retirement and others

1,515

1,267

Total

long-term liabilities

3,484

3,491

Total

liabilities

$ 13,130

$ 14,203

COMMITMENTS

AND CONTINGENT LIABILITIES

Equity:

Common

stock, par value $0.0001 per share; 250,000,000 and 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively;

46,921,061 and 43,532,281 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively

Preferred

C shares, par value $0.0001 per share; 1,172,000 shares authorized at June 30, 2026 and December 31, 2025; 1,718 shares issued

and outstanding at June 30, 2026 and December 31, 2025

Additional

paid-in capital

361,811

357,489

Accumulated

deficit

(330,305 )

(302,292 )

Total

equity

31,511

55,201

Total

liabilities and equity

$ 44,641

$ 69,404

(1)

All 2026 financial information is derived from the Company’s 2026 unaudited financial statements, as disclosed in the Company’s

Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission; all 2025 financial information is derived from the

Company’s 2025 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the

Securities and Exchange Commission.

(2)

All June 30, 2026 financial information is derived from the Company’s 2026 unaudited financial statements, as disclosed in the

Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission. All December 31, 2025 financial information

is derived from the Company’s 2025 audited financial statements as disclosed in the Company’s Annual Report on Form 10-K,

for the twelve months ended December 31, 2025 filed with the Securities and Exchange Commission.

Adjusted

Gross Profit

The

following table reconciles Adjusted Gross Profit to Gross Profit, which we consider to be the most directly comparable GAAP financial

measure. Amounts presented are in thousands of U.S. dollars.

Three

Months Ended

Six

Months Ended

June

30, 2026

June

30, 2025

June

30, 2026

June

30, 2025

Gross

profit

$ (774 )

$ 313

$ (87 )

$ 605

Adjustments:

Inventory

impairment

$ 612

$ 1,085

Customer

credits

$ 734

Adjusted

gross profit

$ 572

$ 313

$ 1,732

$ 605

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (11215 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 17, 2026

Entity File Number

001-35731

Entity Registrant Name

InspireMD,

Inc.

Entity Central Index Key

0001433607

Entity Tax Identification Number

26-2123838

Entity Incorporation, State or Country Code

Entity Address, Address Line One

6303

Waterford District Drive

Entity Address, Address Line Two

Suite 215

Entity Address, City or Town

Miami

Entity Address, State or Province

Entity Address, Postal Zip Code

33126

City Area Code

(888)

Local Phone Number

776-6804

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value per share

Trading Symbol

NSPR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration